Should I Buy NUVB? NUVB 2026 Analysis

Should You Buy Nuvation Bio Inc (NUVB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

5.700

1 Day change

1.42%

52 Week Range

9.750

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: price is sitting near the pivot/support zone (~5.63) after a -3.5% pullback, while momentum (MACD histogram) is turning up.
Options positioning is strongly risk-on (very low put/call ratios), aligning with a bullish Street setup and expectations for continued Ibtrozi launch traction.
Wall Street has been moving targets higher and ratings skew positive; near-term sentiment supports upside attempts back toward 6.04–6.30.
Main drawback: insiders have been selling more aggressively recently, which tempers conviction but doesn’t outweigh the improving commercial/analyst backdrop at this price.

Technical Analysis

Trend/Momentum: MACD histogram is positive (0.0353) and expanding, suggesting improving upside momentum after recent weakness.
RSI: RSI(6) at 43.33 is neutral-to-slightly weak; it’s not overbought, leaving room for a bounce.
Moving averages: converging MAs indicate consolidation rather than a clean trend—often a setup for a directional move.
Key levels: Pivot 5.628 is immediate “line in the sand”; downside supports at 5.215 then 4.96. Upside resistance at 6.04 (R1) then 6.295 (R2).
Near-term pattern stats (similar candlesticks): modest upside bias (next day +2.37%, next week +1.55%, next month +6.9% probabilities/expectations as provided).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Extremely call-skewed positioning (OI put/call 0.19; volume put/call 0.01) implies bullish/speculative appetite.
Activity: Today’s option volume (~1,375) is ~77.7% of 30D average (not a spike), but open interest is solid (total OI ~84,397).
Volatility: 30D IV ~81.26 vs HV ~79.86 (roughly in-line). IV percentile ~23 and IV rank ~4 suggest IV is relatively low vs its own history—often supportive for long premium or directional call interest.
Positioning tilt: Calls dominate (call OI 70,988 vs put OI 13,409), reinforcing bullish bias.

Technical Summary

Sell

Buy

Positive Catalysts

- Commercial ramp: 2025/Q3 revenue surged on a YoY basis (launch/uptake dynamics), consistent with analysts citing strong early Ibtrozi uptake.
- Analyst momentum: multiple firms raised price targets recently (e.g., Truist to $13; RBC to $12; H.C. Wainwright to $18), indicating improving expectations.
- Product narrative: Street commentary highlights Ibtrozi as potentially a preferred ROS1 option with robust early launch metrics.
- Market setup: if support near 5.63 holds, technicals favor a push back toward 6.04–6.30.

Neutral/Negative Catalysts

- Insider activity: insiders are selling, with selling amount up 287.18% over the last month (clear sentiment headwind).
- No near-term news flow: no notable catalysts in the past week; absent fresh updates, the stock may trade technically/market-driven.
- High volatility regime: HV ~79.86 and IV ~81.26 imply large swings are normal for the name.
- Broader tape: S&P 500 down ~1.07% today, which can pressure small/mid-cap biotech risk appetite.

Financial Performance

Latest quarter (2025/Q3): Revenue increased to $13.12M, up 1704.68% YoY (strong launch/early commercial scaling signal).
Profitability trend: Net income improved YoY to -$55.792M (loss narrowing ~35.38% YoY improvement as provided).
EPS: improved to -$0.16 (up 6.67% YoY as provided).
Margin: gross margin reported at 74.47, down YoY per the snapshot—worth watching as commercial mix and launch costs normalize.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Rating trend: Predominantly bullish—multiple Buy/Outperform ratings with one notable Neutral initiation (UBS Neutral, PT $10).
Price target trend: clear upward revisions recently (RBC $9→$12; Truist $11→$13; H.C. Wainwright $10→$18; Wedbush $7→$11; JMP $8→$10), signaling improving confidence.
Wall Street pros: strong early Ibtrozi uptake, commercial-stage transition, and pipeline upside (e.g., safusidenib path) underpin the bull case.
Wall Street cons: pipeline pruning/discontinuations are not viewed as thesis-changing by some, but they remind investors that pipeline execution risk remains.
Influential trading: no recent Congress trading data available; hedge funds flagged as neutral (no significant last-quarter trend).

10 Analyst Rating

Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 11.38 USD with a low forecast of 8 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 5.620

Low

Averages

11.38

High

Current: 5.620

Low

Averages

11.38

High

Truist

Buy

maintain

$11 -> $13

AI Analysis

2026-01-27

Reason

Truist

Price Target

$11 -> $13

AI Analysis

2026-01-27

maintain

Buy

Reason

Truist raised the firm's price target on Nuvation Bio to $13 from $11 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm believes the Ibtrozi franchise has shown robust opportunity out of the gate, with stronger-than-anticipated uptake, despite seasonal headwinds, positioning Ibtrozi as the ROS1 agent of choice versus competitors, the analyst tells investors in a research note.

RBC Capital

Leonid Timashev

Outperform

maintain

$9 -> $12

2026-01-21

Reason

RBC Capital

Leonid Timashev

Price Target

$9 -> $12

2026-01-21

maintain

Outperform

Reason

RBC Capital analyst Leonid Timashev raised the firm's price target on Nuvation Bio to $12 from $9 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NUVB

Unlock Now

NUVB Should I Buy

NUVB Should I Buy

Should You Buy Nuvation Bio Inc (NUVB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch